Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 3, 2010, Pages 249-255

  Raffa, R B ^a   Tallarida, R J ^b  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b School of Veterinary Medicine   (United States)

Author keywords

Adverse effects; Cancer chemotherapy; Chemo brain; Chemo fog; Cognition; Eye

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEFEROXAMINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PENTOSTATIN; TAMOXIFEN; THIOTEPA;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BLEPHARITIS; BLEPHAROCONJUNCTIVITIS; BLURRED VISION; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER STAGING; CHEMO FOG; CIRCUMORBITAL EDEMA; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONJUNCTIVA DISEASE; CONJUNCTIVITIS; CORNEA DISEASE; DRUG ADMINISTRATION ROUTE; DRUG INDUCED DISEASE; DRUG MEGADOSE; ECTROPION; EXCESSIVE LACRIMATION; EYE DISEASE; EYE IRRITATION; EYE PAIN; EYE TOXICITY; HUMAN; INTERNUCLEAR OPHTHALMOPLEGIA; INTRAVENTRICULAR DRUG ADMINISTRATION; KERATITIS; KERATOCONJUNCTIVITIS SICCA; LACRIMAL DUCT OCCLUSION; LACRIMATION DISORDER; MONOTHERAPY; MOTOR PERFORMANCE; NASALACRIMAL DUCT OBSTRUCTION; NERVE FIBER DEGENERATION; NEUROLOGIC EXAMINATION; NOTE; OPTIC NERVE DISEASE; PHOTOPHOBIA; PINPOINT PUPILS; QUANTITATIVE ANALYSIS; RETINA DISEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; DRUG INTERACTIONS; HUMANS; MEMORY DISORDERS; VISUAL PERCEPTION;

EID: 77952217466     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01086.x     Document Type: Note

References (46)

1. Raffa RB, Duong PV, Finney J et al. (2006) Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy? Journal of Clinical Pharmacy and Therapeutics, 31, 129 138.
2. Wieneke MH, Dienst ER (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4, 61 66.
3. Brezden CB, Phillips K-A, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 2695 2701.
4. Schagen SB, van Dam FSAM, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85, 640 650.
5. van Dam FSAM, Schagen SB, Muller MJ, Boogerd W, Wall Evd, Droogleever Fortuyn ME, Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose vs. standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210 218.
6. Lezak M (1993) Neuropsychological Assessment, 2nd edn.
7. Delis DC, Kramer JH, Kaplan E, Ober BA (1987) CVLT Research Edition Manual.
8. Fraunfelder FT, Meyer SM (1983) Ocular toxicity of anineoplastic agents. Ophthalmology, 90, 1 3.
9. Imperia PS, Lazarus HM, Lass JH (1989) Ocular complications of systemic cancer chemotherapy. Survey of Ophthalmology, 34, 209 230.
10. AL-Tweigeri T, Nabholtz J-M, Mackey JR (1996) Ocular toxicity and cancer chemotherapy. Cancer, 78, 1359 1373.
11. Schmid KE, Kornek GV, Scheithauer W, Binder S (2006) Update on ocular complications of systemic cancer chemotherapy. Survey of Ophthalmology, 51, 19 40.
12. Gianni L, Panzini I, Li S et al. (2006) International Breast Cancer Study Group (IBCSG). Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer, 106, 505 513.
13. Jack MK, Hicks JD (1981) Ocular complications in high-dose chemoradiotherapy and marrow transplantation. Annals of Ophthalmology, 13, 709 711.
14. Kende G, Sirkin SR, Thomas PR, Freeman AI (1979) Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer, 44, 69 71.
15. Stevens A, Spooner D (2001) Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer. Clinical Oncology, 13, 438 440.
16. Lee V, Bentley CR, Olver JM (1998) Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy. Eye, 12, 343 349.
17. Esmaeli B, Burnstine MA, Ahmadi MA, Prieto VG (2003) Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthalmic Plastic and Reconstructive Surgery, 19, 305 308.
18. Esmaeli B, Hidaji L, Adinin RB et al. (2003) Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer, 98, 504 507.
19. Vizel M, Oster MW (1982) Ocular side effects of cancer chemotherapy. Cancer, 49, 1999 2002.
20. Rahl AHS, Hungerford JL, Ahmed AI (1988) Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. British Journal of Ophthalmology, 70, 373 381.
21. Voest EE, Neijt JP, Keunen JE et al. (1993) Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemotherapy and Pharmacology, 31, 357 362.
22. Khaw PT, Sherwood MB, MacKay SL, Rossi MJ, Schultz G (1992) Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. Archives of Ophthalmology, 110, 1150 1154.
23. Stern WH, Guerin CJ, Erickson PA, Lewis GP, Anderson DH, Fisher SK (1983) Ocular toxicity of fluorouracil after vitrectomy. American Journal of Ophthalmology, 96, 43 51.
24. Agarwal MR, Esmaeli B, Burnstine MA (2002) squamous metaplasia of the canaliculi associated with 5-fluorouracil: a clinicopathologic case report. Ophthalmology, 109, 2359 2361.
25. Shapiro MS, Thoft RA, Friend J, Parrish RK, Gressel MG (1985) 5-fluorouracil toxicity to the ocular surface epithelium. Investigative Ophthalmology and Visual Science, 26, 580 583.
26. Brink HM, Beex LV (1995) Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Documenta Ophthalmologica, 90, 1 6.
27. Prasad S, Kamath GG, Phillips RP (2000) Lacrimal canalicular stenosis associated with systemic 5-fluorouracil therapy. Acta Ophthalmologica Scandinavica, 78, 110 113.
28. Bixenman WW, Nicholls JVV, Warwick OH (1968) Oculomotor disturbances associated with 5-fluorouracil chemotherapy. American Journal of Ophthalmology, 83, 604 608.
29. Sato Y, Morita M, Takahashi HO, Watanabe N, Kirikae I (1970) Combined surgery, radiotherapy, and regional chemotherapy in carcinoma of the paranasal sinuses. Cancer, 25, 571 579.
30. Fishman ML, Bean SC, Cogan DG (1976) Optic atrophy following prophylactic chemotherapy and cranial radiation for acute lymphocytic leukemia. American Journal of Ophthalmology, 82, 571 576.
31. Margileth DA, Poplack DG, Pizzo PA, Leventhal BG (1977) Blindness during remission in two patients with acute lymphoblastic leukemia: a possible complication of multimodality therapy. Cancer, 39, 58 61.
32. Boogerd W, Moffie D, Smets LA (1990) Early blindness and coma during intrathecal chemotherapy for meningeal carcinomatosis. Cancer, 65, 452 457.
33. Carter WH Jr., Wampler GL, Stablein DM, Campbell ED (1982) Drug activity and therapeutic synergism in cancer treatment. Cancer Research, 42, 2963 2971.
34. Greco WR, Park HS, Rustum YM (1990) Application of a new approach for the quantitation of drug synergism to the combination of cis- diamminedichloroplatinum and 1-ß-D-arabinofuranosylcytosine. Cancer Research, 50, 5318 5327.
35. Raymond E, Djelloul S, Buquet-Fagot C, Mester J, Gespach C (1996) Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells. Anti-Cancer Drugs, 7, 752 757.
36. Hsieh TC, Wu JM (2008) Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. International Journal of Oncology, 33, 851 859.
37. Shuhendler AJ, O'Brien PJ, Rauth AM, Wu XY (2007) On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells. Drug Metabolism and Drug Interactions, 22, 201 233.
38. Pentheroudakis G, Razis E, Athanassiadis A, Pavlidis N, Fountzilas G (2006) Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Medical Oncology, 23, 147 160.
39. McGill TJ, Douglas RM, Lund RD, Prusky GT (2004) Quantification of spatial vision in the Royal College of Surgeons rat. Investigative Ophthalmology and Visual Science, 45, 932 936.
40. Tallarida RJ, Jacob LS (1979) The Dose-Response Relation in Pharmacology.
41. Tallarida RJ, Murray RB (1987) Manual of Pharmacologic Calculations with Computer Programs, 2nd edn.
42. Tallarida RJ, Raffa RB, McGonigle P (1988) Principles in General Pharmacology.
43. Tallarida RJ (2000) Drug Synergism and Dose-Effect Data Analysis.
44. Tallarida RJ (2006) Perspectives in pharmacology: an overview of drug combination analysis with isobolograms. Journal of Pharmacology and Experimental Therapeutics, 319, 1 7.
45. Tallarida RJ (2007) Interactions between drugs and occupied receptors. Pharmacology and Therapeutics, 113, 197 209.
46. Raffa RB, Stone DJ, Tallarida RJ (2000) Discovery of self-synergistic spinal/supraspinal antinociception produced by acetaminophen (paracetamol). Journal of Pharmacology and Experimental Therapeutics, 295, 291 294.